1244P Real-world EGFR and T790M testing patterns in patients from Central Eastern Europe with advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)

Abstract

After an initial response to first- or second-generation (1G/2G) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) roughly one-half of patients (pts) with advanced EGFR mutated (EGFRm) non-small cell lung cancer (NSCLC) develop resistance due to a secondary T790M mutation. REFLECT study (NCT04031898) explored EGFR/T790M testing and treatment patterns in EGFRm NSCLC pts receiving 1G/2G EGFR TKis in 8 countries. Pooled data from Central Eastern Europe (CEE) are presented here.